Medicines

Good Governance for Medicines (GGM)

The Good Governance for Medicines approach is to support policy-makers and national officials to understand where the strengths and weaknesses lie in the national pharmaceutical systems in order to develop and apply appropriate interventions. The programme has now been implemented in 36 countries worldwide.

The need for good governance in the pharmaceutical sector

Increasing access to medicines remains one of the major global challenges to achieve Universal health Coverage. In recent years governance has been identified as being crucial for universal access and sector performance, for example through increasing efficiency and reducing wastage. Good governance has been identified as a priority area of work in the WHO Medicines Strategy 2008-2013.

Additional governance initiatives in the pharmaceutical sector

Good governance and the critical need for evidence on effective interventions to increase access to medicines has been identified as a priority area of work by the WHO Medicines Strategy 2008-2013. Efforts of the Department for Essential Medicines and Health Products to improve good governance in the pharmaceutical sector, through policy and regulatory support initiatives and programmes such as the Medicines Transparency Alliance and Good Governance for Medicines, have generated considerable insight into understanding how good governance can impact on the availability and affordability of quality medicines.

Collaboration

WHO collaborates with many different stakeholders to improve governance in the pharmaceutical sector.

Highlights


Good Governance for Medicines Model Framework 2012

The 2012 model framework is now available for comment until 15 October 2013.


World Health Assembly 66 Side Event
20 May 2013

The findings and the recommendations from the evaluation of the Good Governance for Medicines Programme was presented. The experiences from Thailand and Malawi was also shared in a event held at this year World Health Assembly in Geneva.

Contact

Dr. Gilles Forte
Team Coordinator
Medicines Policy, Governance, Information and Coordination
Department of Essential Medicines and Health Products
Avenue Appia 20 27 Geneva- CH-1211 Switzerland
+41 22 791 36 17
forteg@who.int